Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000360220

Medchemexpress LLC Remogliflozin etabonate | 442201-24-3 | 99.6% | 522.59 | 100 MG
SDP

Catalog No. 5000360220
Encompass_Preferred

Remogliflozin etabonate is an orally active, selective, and low-affinity sodium glucose cotransporter (SGLT2) inhibitor. It acts as a prodrug, converting to its active form, Remogliflozin, within the body. This compound has demonstrated antidiabetic efficacy in various rodent models, offering potential benefits in glucose and lipid metabolism regulation.

  • Orally active and selective SGLT2 inhibitor
  • Functions as a prodrug, metabolized to active Remogliflozin
  • Exhibits antidiabetic efficacy in rodent models
  • Significantly reduces fasting plasma glucose (FPG) and glycated hemoglobin (GHb) levels
  • Ameliorates hyperglycemia and increases urinary glucose excretion
  • Decreases plasma insulin in normal rats
  • Suppresses the development of hypertriglyceridemia

Catalog No. 50-003-60220 Supplier Medchemexpress LLC Supplier No. HY14945100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Remogliflozin etabonate is an orally active, selective, and low-affinity sodium glucose cotransporter (SGLT2) inhibitor. It acts as a prodrug, converting to its active form, Remogliflozin, within the body. This compound has demonstrated antidiabetic efficacy in various rodent models, offering potential benefits in glucose and lipid metabolism regulation.

  • Orally active and selective SGLT2 inhibitor
  • Functions as a prodrug, metabolized to active Remogliflozin
  • Exhibits antidiabetic efficacy in rodent models
  • Significantly reduces fasting plasma glucose (FPG) and glycated hemoglobin (GHb) levels
  • Ameliorates hyperglycemia and increases urinary glucose excretion
  • Decreases plasma insulin in normal rats
  • Suppresses the development of hypertriglyceridemia

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.